Fennec Pharmaceuticals

Fennec Pharmaceuticals is a specialized biotech with a singular mission: to protect the hearing of cancer survivors treated with cisplatin chemotherapy. The company successfully launched Pedmark®, its first commercial product, following FDA approval in 2022. Its current strategy involves driving commercial adoption in pediatrics, pursuing label expansion into adult head & neck and testicular cancers through investigator-sponsored trials, and defending its intellectual property. Fennec represents a focused play on oncology supportive care with a significant unmet medical need.

Fennec's approach is based on the chemoprotectant sodium thiosulfate, which acts to neutralize cisplatin in the inner ear (cochlea) to prevent the formation of reactive oxygen species that cause irreversible damage to sensory hair cells, thereby preventing hearing loss.

Total raised: $45M

Fennec faces no direct FDA-approved competition for preventing cisplatin-induced hearing loss. Its main competitors are reactive measures like hearing aids and dose reduction of cisplatin. Several early-stage pipeline candidates from other companies exist, but Pedmark's first-mover advantage, FDA approval, and growing clinical experience provide a strong, multi-year competitive moat.